Hiromi Muta
Overview
Explore the profile of Hiromi Muta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
663
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muta H, Noda T
Acta Paediatr
. 2025 Jan;
PMID: 39821910
Aim: To investigate children's exposure to secondhand smoke and aerosols in the current era of new tobacco products. Methods: A total of 200 children were recruited from among children who...
2.
Nishimura T, Muta H, Hosaka T, Ueda M
Acta Paediatr
. 2022 Nov;
112(2):323.
PMID: 36427273
No abstract available.
3.
Nishimura T, Muta H, Hosaka T, Ueda M, Kishida K
Acta Paediatr
. 2022 Aug;
111(11):2157-2164.
PMID: 35927828
Aim: The World Health Organization has listed honey as a potential treatment for coughs, but there is little evidence to support its use for coughs associated with upper respiratory tract...
4.
Muta H, Nagai T, Ito Y, Ihara T, Nakayama T
Vaccine
. 2015 Oct;
33(45):6049-53.
PMID: 26431987
Objective: The purpose of this study was to determine the risk of aseptic meningitis after mumps vaccination in younger children compared with older children. Methods: This prospective cohort study included...
5.
Shinoda K, Sun X, Oyamada A, Yamada H, Muta H, Podack E, et al.
J Autoimmun
. 2014 Dec;
57:14-23.
PMID: 25533628
The CD30 ligand (CD30L)/CD30 axis plays a critical role in Th1 and Th17 cell differentiation. However, the role in the pathogenesis of central nervous system autoimmunity remains unknown. Here we...
6.
Muta H, Podack E
Immunol Res
. 2013 Nov;
57(1-3):151-8.
PMID: 24233555
The FDA recently approved an agonistic anti-CD30 drug conjugate, Brentuximab vedotin, for the treatment for CD30-positive lymphomas. The potent clinical activity of Brentuximab vedotin in Hodgkin's lymphoma and anaplastic large-cell...
7.
Guo Y, Sun X, Shibata K, Yamada H, Muta H, Podack E, et al.
Infect Immun
. 2013 Aug;
81(10):3923-34.
PMID: 23918785
Interleukin-17A (IL-17A)-producing γδ T cells are known to be activated following Mycobacterium bovis bacillus Calmette-Guérin (BCG) infection. Here, we show that CD30, a member of the tumor necrosis factor (TNF)...
8.
Somada S, Muta H, Nakamura K, Sun X, Honda K, Ihara E, et al.
Dig Dis Sci
. 2012 Mar;
57(8):2031-7.
PMID: 22451116
Background And Aims: Although CD30 has long been recognized as an important marker in many lymphomas of diverse origin, and as an activation molecule on B and T cells, its...
9.
Muta H, Ishii M, Yashiro M, Uehara R, Nakamura Y
Pediatrics
. 2012 Jan;
129(2):e291-7.
PMID: 22250032
Objective: To evaluate the effectiveness of intravenous immunoglobulin (IVIG) treatment of Kawasaki disease ≥10 days after illness onset. Methods: We selected patients initially treated with IVIG on days 11 to...
10.
Fuchiwaki T, Sun X, Fujimura K, Yamada H, Shibata K, Muta H, et al.
Eur J Immunol
. 2011 Jul;
41(10):2947-54.
PMID: 21739429
CD30 ligand (CD30L) plays an important role in the amplification and/or activation of effector CD4(+) T cells, irrespective of Th cell subset. To examine the role of CD30L in allergic...